EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access

Safety and efficacy of topical diquafosol for the treatment of dry eye disease: An updated meta-analysis of randomized controlled trials

Shuang Liu, Guang Yang, Qingnan Li, Shaohua Tang

Indian Journal of Ophthalmology · 2023

DOI: 10.4103/ijo.ijo_268_23 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Indian Journal of Ophthalmology, 2023. Verfasst von Shuang Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Beijing Jishuitan Hospital, Xicheng District, Beijing, China. Hauptthemen laut MEDLINE: Dry Eye Syndromes, Ophthalmic Solutions, Polyphosphates. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dry eye disease (DED) is a common multi-factorial disease that is characterized by tear film instability. Diquafosol tetrasodium (DQS), an ophthalmic solution, has been shown to be beneficial in the treatment of DED. The goal of this study was to provide an update on the safety and efficacy of topical 3% DQS in treating DED patients. A thorough search for all the published randomized controlled trials (RCTs) up to March 31, 2022 in CENTRAL, PubMed, Scopus, and Google Scholar databases was performed. Data were reported as standardized mean difference (SMD) with 95% confidence interval (CI). Modified Jadad scale was used for sensitivity analysis. Funnel plot and Egger’s regression test assessed the publication bias. Fourteen RCTs evaluating the safety and efficacy of topical 3% DQS treatment in DED patients were included. Eight included RCTs reported data on the DED after cataract surgery. Overall findings suggest that 3% DQS treatment in DED patients was associated with significantly better improvement at 4 weeks in tear breakup time, Schirmer test, fluorescein staining scores, and Rose Bengal staining score as compared to patients treated with others eye drops including artificial tears or 01% sodium hyaluronate. However, no significant difference in ocular surface disease index was observed. Our findings suggest that 3% DQS treatment is safer and had a superior efficacy compared to artificial tears or sodium hyaluronate for treating DED in general and DED after cataract surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dry Eye SyndromesOphthalmic SolutionsPolyphosphatesHumansHyaluronic AcidLubricant Eye DropsRandomized Controlled Trials as TopicTearsCataract ExtractionUracil Nucleotides

Stichwörter der Autor:innen

3% diquafosolartificial tearsdry eye diseaseefficacyeye dropssafety

Substanzen

diquafosolHyaluronic AcidLubricant Eye DropsOphthalmic SolutionsPolyphosphatesUracil Nucleotides

Autor:innen und Institutionen

  • Department of Ophthalmology, Beijing Jishuitan Hospital, Xicheng District, Beijing, China.

Zitieren

APA

Liu, S., Yang, G., Li, Q., & Tang, S. (2023). Safety and efficacy of topical diquafosol for the treatment of dry eye disease: An updated meta-analysis of randomized controlled trials. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_268_23

Vancouver

Liu S, Yang G, Li Q, Tang S. Safety and efficacy of topical diquafosol for the treatment of dry eye disease: An updated meta-analysis of randomized controlled trials. Indian Journal of Ophthalmology. 2023. doi:10.4103/ijo.ijo_268_23

BibTeX
@article{Liu2023,
  author = {Liu, Shuang and Yang, Guang and Li, Qingnan and Tang, Shaohua},
  title = {Safety and efficacy of topical diquafosol for the treatment of dry eye disease: An updated meta-analysis of randomized controlled trials},
  journal = {Indian Journal of Ophthalmology},
  year = {2023},
  doi = {10.4103/ijo.ijo_268_23}
}
Kostenlos starten →